BRAF V600E Mutation in Malignant Melanoma-A Romanian Research Experience.

Medicina (Kaunas)

Department of Morpho-Functional Sciences I-Histology, Pathology, "Grigore T. Popa" University of Medicine and Pharmacy, 16 University Street, 700115 Iași, Romania.

Published: February 2024

: The most common mutation in malignant melanoma (MM) is the single-point mutation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) oncogene. Our study aims to evaluate BRAF V600E mutation, highlighting its frequency differences in primary versus metastatic MM. : The study group comprised 133 patients diagnosed with MM in several county hospitals of the north-eastern region of Romania who have been assigned for investigation into BRAF V600E mutation in the private medical system. The material consisted of archived formalin-fixed paraffin-embedded (FFPE) blocks. BRAF V600E mutation was identified using the fully automated Idylla BRAF mutation test system. : Out of the total of 133 cases, 78 cases were primary tumors, while 55 cases were metastatic MMs. Genetic analysis revealed the presence of BRAF V600E mutation in 66 cases (49.62%) and the wild-type genotype in 67 cases (50.37%). We found a statistically significant difference of the mutation frequency according to age ( = 0.0072). The mutated genotype was found in 45 cases out of 78 primary MMs (57.69%) and in 21 cases out of 55 secondary MMs (38.18%), with a statistically significant difference in favor of primary tumors ( = 0.0413). The correlations between the histopathological types, Clark's level, Breslow index, ulceration, and lymphovascular invasion, respectively, and the mutated genotype were not statistically significant. BRAF V600E mutation was identified in 15 out of 40 secondary tumors with lymph node location (37.5%) and in 6 out of 15 secondary tumors with another location (40%) without statistically significant differences between the mutation frequency and the location of the secondary tumors. : Our results support MM high genetic heterogeneity, pointing out the relationship between BRAF V600E mutation and several clinicopathological characteristics, in primary and metastatic MMs, stressing the importance of BRAF testing implementation in Romania.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10971826PMC
http://dx.doi.org/10.3390/medicina60030351DOI Listing

Publication Analysis

Top Keywords

braf v600e
28
v600e mutation
28
mutation
12
secondary tumors
12
braf
10
mutation malignant
8
mutation identified
8
cases primary
8
primary tumors
8
metastatic mms
8

Similar Publications

BRAF-activated ARSI suppressed EREG-mediated ferroptosis to promote BRAF (mutant) papillary thyroid carcinoma progression and sorafenib resistance.

Int J Biol Sci

January 2025

Department of Thyroid and Hernia Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou City, Fujian Province 350001, China.

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, and patients with the BRAF mutation often exhibit aggressive tumor behavior. Here, we identified Arylsulfatase I (ARSI) as a gene whose expression was significantly upregulated in BRAF PTC and was associated with poor prognosis. High ARSI expression correlated with advanced disease stage, BRAF mutation, and worse overall survival in PTC patients.

View Article and Find Full Text PDF

[Correlation of Mutation with Clinical Features and Prognosis of Langerhans Cell Histiocytosis in Cildren].

Zhongguo Shi Yan Xue Ye Xue Za Zhi

December 2024

Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing 400014, China.

Objective: To explore the gene mutations of Langerhans cell histiocytosis in children, and to analyze the correlation of mutation with clinical features and prognosis of LCH, so as to provide reference for clinical diagnosis and treatment.

Methods: Fluorescence PCR was used to detect gene mutations in paraffin-embedded tissue samples from 78 children with LCH, and the correlation of mutation with clinical characteristics and prognosis of LCH in children was analyzed.

Results: Among the 78 children, 41 cases (52.

View Article and Find Full Text PDF
Article Synopsis
  • Colorectal cancer is the third most common cancer, and managing unresectable metastatic cases, especially those with MSS and BRAF V600E mutation, poses significant challenges for treatment.
  • Two case reports illustrate the effectiveness of an alternating chemotherapy regimen (irinotecan and oxaliplatin along with capecitabine and bevacizumab) in two patients with MSS, BRAF V600E-mutated stage IV metastatic CRC, demonstrating a partial response and dropping carcinoembryonic antigen levels.
  • The study suggests that this alternating regimen offers a promising treatment strategy with improved progression-free survival compared to standard first-line therapies, making it a potential first-line option for patients with this specific type of colorectal cancer.
View Article and Find Full Text PDF

Real-World Evidence of the Prevalence of Driver Mutations in Anorectal Melanoma.

Mol Diagn Ther

December 2024

Comprehensive Cancer Center, University of Maastricht, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands.

Introduction: Anorectal melanoma is a rare neoplasm with an aggressive behavior and poor prognosis. Recently, recurrent gene mutations related to anorectal melanoma have been identified in a small series of cases, and this holds promise for targeted therapies, analogous to cutaneous melanoma. The purpose of this study was to analyze testing rates and prevalence of mutations in anorectal melanoma in the Dutch population.

View Article and Find Full Text PDF

Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are exceptionally rare disorders characterized by varied clinical presentations, posing several challenges for clinicians. The concomitant occurrence of LCH and ECD is exceedingly rare and has no known etiology. In this report, we present a rare case of mixed histiocytosis (both ECD and LCH) with multisystem involvement.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!